Ocriplasmin
- Generic Name
- Ocriplasmin
- Brand Names
- Jetrea
- Drug Type
- Biotech
- CAS Number
- 1048016-09-6
- Unique Ingredient Identifier
- 7V6HE3DM5A
- Background
Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.
- Indication
Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.
- Associated Conditions
- Symptomatic Vitreomacular Adhesion (VMA)
Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 19
- Registration Number
- NCT00123292
- Locations
- 🇧🇪
University Hospital Gasthuisberg, Leuven, Belgium
Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy
- Conditions
- Vitreomacular Traction MaculopathyEye Diseases
- Interventions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 60
- Registration Number
- NCT00123279
- Locations
- 🇳🇱
Oogziekenhuis Rotterdam, Rotterdam, Netherlands
🇧🇪University Hospital Gasthuisberg, Leuven, Belgium
🇳🇱Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 40
- Registration Number
- NCT00123305
- Locations
- 🇦🇹
Allgemeines Offentliches Krankenhaus der, Linz, Austria
🇧🇪Cliniques Universitaires St Luc, Brussels, Belgium
🇦🇹Landesnervenklinik Wagner-Jauregg, Linz, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.